Table S2.
Detailed clinical and microbiological features of CR-hvKp strains
| Clinical features | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 | P10 | P11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 87 | 87 | 87 | 88 | 79 | 71 | 65 | 65 | 77 | 84 | 94 |
| Gender | F | M | M | F | M | F | F | M | M | M | M |
| Clinical department | Internal medicine | Emergency | General surgery | ICU | General surgery | ICU | ICU | Thoracic surgery | ICU | Thoracic surgery | Respiratory |
| Main underlying diseases | Bone fracture; Cardiovascular diseases | Diabetes | Surgery with in 1 month | Cerebrovascular disease | Cancer; Surgery with in 1 month | Cancer; Surgery with in 1 month | Diabetes; Cerebrovascular disease | Cancer | Cancer; Surgery with in 1 month | Surgery with in 1 month | Cancer; Cerebrovascular disease; diabetes |
| Tube | CVC; Ureter | Ureter; Stomach tube | None | CVC; Ureter; Stomach tube; Tracheal catheter | CVC; Ureter; Stomach tube; Tracheal catheter | CVC; Ureter; Tracheal catheter | CVC; Ureter; Stomach tube; Tracheal catheter | CVC; Ureter; Stomach tube; Tracheal catheter | CVC; Ureter; Stomach tube; Tracheal catheter | CVC; Ureter; Stomach tube; Tracheal catheter | CVC; Ureter; Stomach tube; Tracheal catheter |
| Specimen type | Sputum | Sputum | Pyogenic fluids | Bile | Sputum +Blood +Wound | Bile+Blood | Sputum+Urine +Feces | Sputum | Pyogenic fluids | Sputum+Urine | Drainage liquid |
| Infection type | Pneumonia | Pneumonia | Abscess | PLA | Sepsis | Septic shock | Septic shock | Sepsis | Septic shock | Septic shock | Sepsis |
| WBC(109/L) | 12.21 | 10.85 | 13.76 | 16.44 | 8.80 | 15.49 | 10.0 | 18.32 | 11.66 | 9.51 | 4.64 |
| NEU (%) | 75.1 | 86.6 | 92.5 | 82.2 | 56.8 | 83.4 | 69.9 | 87.4 | 88.0 | 65.2 | 68.3 |
| TP (g/L) | 79.4 | 60.5 | 69.4 | 52.8 | 54.7 | 49.6 | 59 | 70.9 | 62 | 67.4 | 61.2 |
| ALB (g/L) | 40.3 | 27.7 | 34.6 | 28.2 | 20.6 | 30.0 | 32.6 | 36.4 | 27.4 | 31.7 | 35.0 |
| Sensitive antibiotics | N | N | N | N | GEN; LEV; TOB | N | SMZ; TOB; AMK | SMZ | N | N | SMZ; AMK |
| SOFA score | 6 | 10 | 2 | 13 | 7 | 9 | 7 | 4 | 5 | 6 | 7 |
| Empiric therapy | CIP+CAZ | CIP+CAZ | IPM | IPM+ISE | IPM+MXF | CIP+CAZ | IPM+ISE | IPM | IPM | MXF | MEM |
| Switched therapy | MEM+TGC | MEM+TGC | TGC | TGC | GEN+LEV | TGC+MEM | TGC+MEM+FOS | TGC+MEM | TGC+MEM | TGC+MEM+FOS | TGC |
| Clinical outcome | Survived | Survived | Survived | Survived | Survived | Survived | Survived | Died | Survived | Survived | Survived |
| String test | + | + | + | + | + | + | + | − | − | + | + |
| Virulence-associated genes | |||||||||||
| rmpA | + | + | + | + | + | + | + | − | − | + | + |
| rmpA2 | + | + | + | + | + | + | + | − | − | + | + |
| magA | + | + | + | + | + | + | + | − | + | + | + |
| cps genes | |||||||||||
| K1 | + | − | − | + | + | + | + | − | − | + | − |
| K2 | + | + | + | + | + | + | + | − | − | + | − |
| K5 | − | − | − | − | − | − | − | + | + | − | − |
| K20 | − | + | − | − | + | − | − | − | + | − | − |
| K54 | − | − | − | − | − | − | + | − | − | − | − |
| K57 | + | − | − | − | − | + | − | − | − | − | − |
| MLST genotyping | 23 | 23 | 17 | 17 | 347 | 17 | 2905 | 2906 | 23 | 412 | 2874 |
Abbreviations: ALB, albumin; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CMZ, cefmetazole; CVC, central venous catheter; F, female; FOS, fosfomycin; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; ISE, isepamicin; LEV, levofloxacin; MLST, multilocus sequence typing; M, male; MEM, meropenem; Mo, month; MXF, moxifloxacin; NEU, neutrophils; N, no; PLA; pyogenic liver abscess; SMZ, sulfamethoxazole; SOFA, sequential organ failure assessment; TGC, tigecycline; TOB, tobramycin; TP, total protein; TZP, piperacillin tazobactam; WBC, white blood cell; Y, yes; +, positive; −, negative.